Shows
Blood Cancer TalksEpisode 63. Management of Follicular Lymphoma with Dr. Gilles SallesIn this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/4. RELEVANCE RCT: Lenalidomide plus R...2025-07-2551 minBlood Cancer TalksEpisode 62. Unpacking MIDAS Trial in Myeloma with Dr. Meera MohanIn this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan. https://pubmed.ncbi.nlm.nih.gov/39841461/https://pubmed.ncbi.nlm.nih.gov/40459097/2025-07-0925 minBlood Cancer TalksEpisode 61. Menin Inhibitors in AML with Dr. Eytan SteinIn this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/d...2025-06-2456 minBlood Cancer TalksEpisode 60. Emergency Podcast-AQUILA and STARGLOIn this episode, we discuss the recent proceedings at the FDA ODAC meeting on AQUILA trial in smoldering myeloma and STRAGLO in R/R DLBCL, and provide an update to our audience on some of the clinically relevant data presented from those trials, along with insights from the panelists. Here is the link to the webpage with FDA briefing documents and slides: https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025#event-materialsHere is the youtube link for FDA proceedings: https://www.youtube.com/watch?v=5ecyDbK9ezc2025-05-2854 minBlood Cancer TalksEpisode 59. Management of Systemic Mastocytosis with Dr. Daniel DeAngeloIn this episode, we discussed the management of systemic mastocytosis with Dr. Daniel DeAngelo from the Dana Farber Cancer Institute. Here are the key studies we discussed:Midostaurin https://www.nejm.org/doi/10.1056/NEJMoa1513098?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.govAvapritinibEXLPORER study: https://www.nature.com/articles/s41591-021-01538-9PATHFINDER study: https://www.nature.com/articles/s41591-021-01539-8Bezuclastinib: APEX trial: https://ashpublications.org/blood/article/144/Supplement%201/659/530240/Apex-Part-1-Updated-Assessment-of-BezuclastinibHSCT for Advanced SM: https://ascopubs.org/doi/10.1200/JCO.2014.55.20182025-05-081h 03Blood Cancer TalksEpisode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers BlomberyIn this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed: 1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/2. CTT...2025-03-2650 minBlood Cancer TalksEpisode 57. ASH 2024 Update on Leukemia/Myeloid Neoplasms with Dr. Jayastu SenapatiIn this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.htmlAbstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.htmlAbstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.htmlVenetoclax resistance mechanismshttps://pubmed.ncbi.nlm.nih.gov/39478230/2025-03-1955 minBlood Cancer TalksEpisode 56. Management of Newly Diagnosed CML with Dr. Hagop KantarjianIn this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/33414482/ 4. 10-year follow-up of CML-IV RCT (imatinib): https://pubmed.ncbi.nlm.nih.gov/25676422/ 2025-02-121h 02Blood Cancer TalksEpisode 55. ASH 2024 Myeloma Updates with Dr. Rakesh PopatIn this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMMOverview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara. Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm. Read the abstract. Read the simultaneous publication at NEJM. 2. Anito-Cel: New BCMA CAR T Therapy Ea...2025-01-1138 minBlood Cancer TalksEpisode 54. ASH 2024 Lymphoma and CLL Highlights with Dr. David Russler-GermainIn this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.htmlb) ENRICH Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.htmlc) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/as...2024-12-2258 minBlood Cancer TalksEpisode 53. Belantamab Makes a Comeback with Dr. Hang QuachIn this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.75022024-11-1344 minBlood Cancer TalksEpisode 52. Management of Hodgkin Lymphoma in Older Adults with Dr. Andrew EvensIn this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm...2024-10-2642 minBlood Cancer TalksEpisode 51. Venetoclax in AML with Dr. Andrew WeiIn this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa20129712. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract3. Genetic Risk Stratification and Outcomes with AML treated with venetoclax and azacitidine https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024024944/517355/Genetic-Risk-Stratification-and-Outcomes-Among4. Genetic risk classification for adults with AML receiving l...2024-09-2756 minBlood Cancer TalksEpisode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy SchmidtIn this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.nc...2024-08-2941 minBlood Cancer TalksEpisode 49. Updates on Low-Risk MDS with Dr. Maximilian StahlIn this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercepthttps://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 3. COMMANDS trial : Luspatercept https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstracthttps://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/ab...2024-08-1443 minBlood Cancer TalksEpisode 48. Management of Polycythemia Vera with Dr. Aaron GerdsIn this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring systemhttps://pubmed.ncbi.nlm.nih.gov/31945802/2. REVEAL studyhttps://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell3. MAJIC PV studyhttps://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed4. Cyto-PV Studyhttps://www.nejm.org/doi/full/10.1056/NEJMoa12085005. PROUD-PV and CONTINUATION-PV trialshttps://www.th...2024-07-2157 minBlood Cancer TalksEpisode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria IacoboniIn this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCLhttps://library.ehaweb.org/eha/2024/eha2024-congress/4136516 2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):https://library.ehaweb.org/eha/2024/eha2024-congress/422343 3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abst...2024-07-0647 minBlood Cancer TalksEpisode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni MohyuddinIn this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed:1. Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL02. EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/38768337/3. Predictors of un-sustained MRD-negativity in multiple myeloma: a) S...2024-06-0957 minBlood Cancer TalksEpisode 45. Updates in Primary Myelofibrosis with Dr. Ayalew TefferiIn this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis § https://ascopubs.org/doi/10.1200/JCO.2018.78.9867?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed · TRANSFO...2024-05-291h 00Blood Cancer TalksEpisode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni MohyuddinIn this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed:1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs observation): https://pubmed.ncbi.nlm.nih.gov/30559051/ 3. Outcomes of lenalidomide maintenance stratified by cytogenetic subgroups (Secondary analysis of Myeloma XI): https://pubmed.ncbi.nlm.nih.gov/36564045/ 4. Cana...2024-05-0152 minBlood Cancer TalksEpisode 43. Essential Thrombocythemia with Dr. Raajit RampalIn this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes:1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status:· Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated· Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated· Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated· High risk: History of thrombosis (any age/genotype), or age >60 years with JAK2 mutationhttps://ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International 2. The MIPSS-ET provides points...2024-04-1835 minBlood Cancer TalksEpisode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al HadidiIn this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4:https://www.youtube.com/watch?v=VSjdGeeXb402024-03-2754 minBlood Cancer TalksEpisode 41. Career Development as a Clinician-Investigator with Dr. Ayalew TefferiIn this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic. 2024-03-1447 minBlood Cancer TalksEpisode 40. Management of Newly Diagnosed AL Amyloidosis with Dr. Angela DispenzieriIn this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed:1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/ 4. Renal staging: https://pubmed.ncbi.nlm.nih.gov/25115890/ 5. Hematologic and cardiac response criteria in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/23091105/...2024-02-2152 minBlood Cancer TalksEpisode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand PatelIn this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed:1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis https://ash.confex.com/ash/2023/webprogram/Paper173509.html 2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study https...2024-02-0855 minBlood Cancer TalksEpisode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan HoltanIn this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed:1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation. https://pubmed.ncbi.nlm.nih.gov/30824040/ 2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis https://pubmed.ncbi.nlm.nih.gov/37342922/ 2024-01-1952 minBlood Cancer TalksEpisode 37. ASH 2023 Myeloma Recap with Dr. Ben DermanIn this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): https://ash.confex.com/ash/2023/webprogram/Paper188547.html https://ash.confex.com/ash/2023/webprogram/Paper182661.html2. PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper191911.html ...2023-12-271h 01Blood Cancer TalksEpisode 36. ASH 2023 Lymphoma Recap with Dr. Toby EyreIn this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relaps...2023-12-2050 minBlood Cancer TalksEpisode 35. Bispecific Antibodies in Lymphoma with Dr. Michael DickinsonIn this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36548927/ 4. Phase 2 trial of mosunetuzumab in relapsed/refractory foll...2023-11-301h 08Blood Cancer TalksEpisode 34. Management of FLT3 AML with Dr. Alexander PerlIn this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.Here are the shownotes:1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutationhttps://www.nejm.org/doi/full/10.1056/nejmoa1614359 3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialhttps://www.thelancet.com/jou...2023-11-171h 08Blood Cancer TalksEpisode 33. The art of caring for patients at the end of life with Dr. Azra RazaIn this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza. We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair. Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/dp/15416995212023-11-0159 minBlood Cancer TalksEpisode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin KaiserIn this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes:1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/Rfonsi1/status/1206004966294294528?s=20 2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:https://pubmed.ncbi.nlm.nih.gov/28655925/ 3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):ht...2023-10-1858 minBlood Cancer TalksEpisode 31. Management of CNS LymphomaIn this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1 2. Elizabeth Schorb ASH 2022 (MARTA) 65-80 year olds – https://ashpublications.org/blood/article/140/Supplement%201/1773/493224/High-Dose-Chemotherapy-and-Autologous-Stem-Cell?searchresult=1 3. IESLG 32 study (MATRIX) - https://pubmed.ncbi.nlm.nih.gov/27132696/ and https://pubmed.ncbi.nlm.nih.gov/35562406/ 4. R-methotrexate procarbazine (PRIMAIN) - https://www.ncbi.nlm.nih.gov/pmc/articles...2023-10-0451 minBlood Cancer TalksEpisode 30. Management of High-Risk MyelomaIn this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon:1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:https://pubmed.ncbi.nlm.nih.gov/34092058/ 3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):https://pubmed.ncbi.nlm.nih.gov/32157174/ ...2023-09-131h 08Blood Cancer TalksEpisode 29. Management of Peripheral T-Cell LymphomaIn this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma?”:https://pubmed.ncbi.nlm.nih.gov/24615779/2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:https://pubmed.ncbi.nlm.nih.gov/34921960/3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:https://pubme...2023-08-3056 minBlood Cancer TalksEpisode 28. Management of CCUSIn this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes:1. CCUS and risk of transformation to myeloid neoplasms:https://www.sciencedirect.com/science/article/pii/S0006497121013471 2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis:https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200310 3. CHRS risk score:http://www.chrsapp.com...2023-08-1847 minBlood Cancer TalksEpisode 27. Management of PNHIn this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky. Here are the shownotes for key papers we discussed in the episode:How I treat PNH: https://pubmed.ncbi.nlm.nih.gov/33512400/Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia: https://pubmed.ncbi.nlm.nih.gov/37084383/Pegcetacoplan versus eculizumab in PNH: a) https://pubmed.ncbi.nlm.nih.gov/33730455/ b) https://pubmed.ncbi.nlm.nih.gov/35349667/Phase 2 study of danicopan (factor d inhibitor) in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to...2023-07-311h 03Blood Cancer TalksEpisode 26. Management of Newly Diagnosed Hodgkin's LymphomaIn this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.Link for our Blood Cancer Talks Survey: https://bit.ly/BCTSHere are the key trials we discussed:1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/27332902/ 2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/27069074/ 3. ECHELON-1 (Replacing Bleomy...2023-07-1557 minBlood Cancer TalksEpisode 25. Managing Acute Toxicities of CAR T-cell TherapyIn this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-L...2023-06-2849 minBlood Cancer TalksEpisode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in MyelomaIn this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf92. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/3. Clinical trials of GPRC5D CAR...2023-06-1747 minBlood Cancer TalksEpisode 23. Bispecific Antibodies in MyelomaIn this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/4876193. Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/4. Phase 1 trial of fixed-duration cevostamab: https://ashpublications.org/blood/article/140/Supplement%201/4415/4923395. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/6. Pa...2023-05-3151 minBlood Cancer TalksEpisode 22. Management of Low-Risk MDSIn this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed:1. ASH choosing wisely: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely 2. International Consensus Classification (ICC): https://pubmed.ncbi.nlm.nih.gov/35767897/ 3. WHO classification 2022: https://pubmed.ncbi.nlm.nih.gov/35732829/ 4. I...2023-05-201h 03Blood Cancer TalksEpisode 21. Newly Diagnosed Mantle Cell LymphomaIn this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes:2:11 How to diagnose mantle cell lymphoma (MCL)?6:51 Clinical manifestations of mantle cell lymphoma7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67?17:21 Overview on treatment of newly diagnosed MCL19:03 Are all cytarabine-based regimens for MCL created equally? RCT of Autologous Transplantation in MCL: https://pubmed.ncbi.nlm.nih.gov/15591112/...2023-05-0346 minBlood Cancer TalksEpisode 20. Management of Myeloma in LMICsIn this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “The Underrepresented Majority”, which highlighted the lack of access to some of the basic anti-myeloma drugs in LMICs and the resulting disparity in global outcomes. Here are some of the sections discussed in this episode:03:33 Diagnostic workup of myeloma in LMICs15:46 Induction therapy for new diagnosed transplant-eligible myeloma2023-04-1957 minBlood Cancer TalksEpisode 19. Management of Primary MyelofibrosisIn this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode:1. Risk stratification of PMF: MIPSS70 Score: http://www.mipss70score.ithttps://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886Genetically inspired prognostic scoring system (GIPSS):https://www.nature.com/articles/s41375-018-0107-zType 1 CALR mutation: https://ashpublications.org/blood/article/124/15/2465/33454MYSEC-PM:http://www.mysec-pm.euhttps://www.nature.com/articles/leu20171692023-04-0659 minBlood Cancer TalksEpisode 18. Management of Smoldering Multiple Myeloma1. How I Approach Smoldering Myeloma (Vaxman and Gertz):https://ashpublications.org/blood/article/140/8/828/485274 2. Risk-Stratification Models in SMM:Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/ 3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):https://pubmed.ncbi.nlm.nih.gov/36067617/ 4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):h...2023-03-2246 minBlood Cancer TalksEpisode 17. Acquired Aplastic AnemiaIn this episode, we discuss the management of acquired aplastic anemia with Dr. Amy DeZern. Here are the links to some of the key articles discussed in this show:1. Review article on aplastic anemia: https://www.nejm.org/doi/10.1056/NEJMra1413485 2. RCTs testing whether addition of cyclosporine to ATG improves outcomes in aplastic anemia:https://www.nejm.org/doi/10.1056/NEJM199105093241901https://www.sciencedirect.com/science/article/pii/S0006497120489748 3. RCT testing horse versus rabbit ATG in aplastic anemia:https://www.nejm.org/doi/ful...2023-03-0846 minBlood Cancer TalksEpisode 16. ASH 2022 Leukemia and Myeloid Malignancies Recap1. Phase III ASAP trialhttps://ash.confex.com/ash/2022/webprogram/Paper159962.html 2. Phase III Dauno-Double Trialhttps://ash.confex.com/ash/2022/webprogram/Paper157126.html 3. Reduced venetoclax exposure: https://ash.confex.com/ash/2022/webprogram/Paper165464.html 4. Menin Inhibitors in AML https://ash.confex.com/ash/2022/webprogram/Paper164849.htmlhttps://ash.confex.com/ash/2022/webprogram/Paper167412.html 5. Imetelstat in MDS: IMerge Phase 2https://ash.confex.com/ash/2022/webprogram...2023-02-2555 minBlood Cancer TalksEpisode 15. Management of Newly Diagnosed DLBCL (Including Bonus ASH22 Updates)In this episode, we discuss the management of newly diagnosed DLBCL with Dr. Pallawi Torka. We also have a few bonus ASH22 updates on DLBCL. Links to articles and abstracts discussed in the episode are as follows: 1. A comprehensive review article on DLBCL:https://pubmed.ncbi.nlm.nih.gov/33657296/ 2. RCT testing CHOP vs Three Intensive Regimens in DLBCL:https://www.nejm.org/doi/full/10.1056/nejm199304083281404 3. RCT testing R-CHOP vs CHOP in DLBCL in older adults:https://www.nejm.org/doi/full/10.1056/nejmoa011795 2023-02-0853 minBlood Cancer TalksEpisode 14. MRD in Multiple Myeloma1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma: https://www.nature.com/articles/s41375-020-01012-42. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group: https://pubmed.ncbi.nlm.nih.gov/35560160/3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/33284948/4. MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple myeloma : https://pubmed.ncbi.nlm.nih.gov/34898239/2023-01-2553 minBlood Cancer TalksEpisode 13. Management of Newly Diagnosed Younger Adults with AMLStudy showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/nejmoa1614359 Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet (ELN) https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 ASH 2022 abstract presenting Daunorubicin 60 Vs 90 mg/m2 https://ash.confex.com...2023-01-1149 minBlood Cancer TalksEpisode 12. ASH 2022 Myeloma Recap1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper159606.htmlhttps://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.https://ash.confex.com/ash/2022/webprogram/Paper170166.htmlLink to the model: https://istopmm.com/riskmodel/ 3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed mult...2022-12-281h 02Blood Cancer TalksEpisode 11. ASH22 Recap: Lymphoma and CLLALPINE Trial: Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (https://www.nejm.org/doi/full/10.1056/NEJMoa2211582) CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html) AVO Trial: Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease (https://ash.confex.com/ash/2022/webprogram/Paper168003.html) Watch-and-Wait RCT in Follicular Lymphoma: Long-term follow-up of Phase 3 Study of Rituximab Versus a Wat...2022-12-2139 minBlood Cancer TalksEpisode 10. Castleman DiseaseExcellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-diseaseInternational consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatmentSomatic alterations in Castleman Disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/https://www.nature.com/articles/s41375-018-0323-6Rituximab + Liposomal Doxorubicin in HHV8-positive MCD: https://ashpublications.org/blood/article/124/24/3544/33494/Rituximab-plus-liposomal-doxorubicin-in-HIVRCT on Siltuximab for MCD: https://pubmed.ncbi.nlm.nih.gov/25042199/Long-term data on...2022-11-3056 minBlood Cancer TalksEpisode 9. CAR-T cell therapy in LymphomaIn this episode, we discussed the three CD19-directed chimeric antigen receptor (CAR T-cell) therapies that have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy: Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447Tisagenlecleucel (tisa-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1804980Lisocabtagene maraleucel (lisocel)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31366-0/fulltext2. Next, we delved into the three prospective phase 3 randomized clinical trials that were conducted to define the optimal second-line treatment by comparing each of the CAR T-cell products to the current standard of ca...2022-11-1651 minBlood Cancer TalksEpisode 8. Management of Newly Diagnosed CLLKey articles and trials discussed in the episode:1. Excellent review in NEJM on treatment of CLL (2020): https://www.nejm.org/doi/full/10.1056/NEJMra19082132. Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa18128363. E1912 (Ibrutinib vs chemoimmunotherapy in younger/fit patients with CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa18170734. RCT testing Acalabrutinib vs Ibrutinib (non-inferiority) in relapsed CLL: https://ascopubs.org/doi/10.1200/JCO.21.012105. ELEVATE-TN Study (Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(2...2022-10-261h 02Blood Cancer TalksEpisode 7. Newly Diagnosed Ph-negative ALLKey papers discussed in the show: 1. Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and2. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.276173. Rituximab in B-ALL https://www.nejm.org/doi/full/10.1056/NEJMoa16050854. A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia: SWOG 1318 https://ascopubs.org/doi/abs/10.1200/JCO.21.017665. Blinatumomab for MRD in adults with B-A...2022-10-1348 minBlood Cancer TalksEpisode 6. Donor Search for Allogeneic Hematopoietic Stem Cell TransplantKey papers discussed in the show:1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa15001403. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.035024. Review/perspective on fundamentals of unrelated donors and cord blood units: https://ashpublications.org/blood/article/120/2/259/30405/A-perspective-on-the-selection-of-unrelated-donors5. HLA-DQ heterodimers and HCT: https://ashpublications.org/blood/article-abstract/139/20/3009/484363/HLA-DQ-heterodimers-in-hematopoietic-cell6. PT-Cy as GVHD prophylaxis after HCT: https://pubmed.ncbi.nlm.nih.gov/20124511/7. Comparative...2022-09-2848 minBlood Cancer TalksEpisode 5. Mentorship and Career DevelopmentIn this episode, we do a thought provoking discussion with Dr. Marty Tallman on mentorship and career development in academic hematology and medical oncology. A must listen for all trainees and early career clinical investigators. Sage wisdom from a legend in the field!2022-09-1440 minBlood Cancer TalksEpisode 4. Measurable Residual Disease in AML2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.70062022-08-241h 02Blood Cancer TalksEpisode 3. Management of Waldenström Macroglobulinemiahttps://ascopubs.org/doi/abs/10.1200/JCO.22.004952022-08-1046 min
Blood Cancer TalksEpisode 2. CAR T-Cell Therapy in Multiple MyelomaIn this episode, we discuss with Dr. Surbhi Sidana the latest advances, practical aspects of patient management, and future directions of cellular therapies in multiple myeloma.2022-07-2731 min
Blood Cancer TalksEpisode 1. Implications of Clonal HematopoiesisIn this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis. 2022-07-1550 min
Blood Cancer TalksIntroduction to BloodCancerTalksBloodCancerTalks is a new podcast focusing exclusively on hematologic malignancies. We will bring a wide range of experts to dig deep into specific topics and critically appraise the literature.
Raj Chakraborty is a hematologist/oncologist and an Assistant Professor of Medicine at Columbia University. Ash Kishtagari is a hematologist/oncologist and an Assistant Professor of Medicine at Vanderbilt University. 2022-07-0802 min